CDI(US:CODX) Prnewswire·2024-09-05 13:30Core Insights - Co-Diagnostics, Inc. has conducted an in silico analysis of its CoDx™ Logix Smart® Mpox (2-Gene) RUO test, confirming that the test maintains full reactivity against circulating mpox strains, including clade Ib [1] - The Africa CDC and WHO have declared mpox a public health emergency, with over 22,800 cases and 622 deaths reported in Africa, highlighting the increased transmissibility and severity of clade Ib compared to other strains [2] - Co-Diagnostics has developed two RUO tests for mpox on its patented Co-Primers® platform, with the 2-gene version showing superior detection capabilities from saliva samples in a study published in December 2023 [3] Company Developments - The CEO of Co-Diagnostics emphasized the company's commitment to advancing PCR testing solutions, including a new at-home and point-of-care PCR platform aimed at tracking infectious disease outbreaks [4] - The company has received numerous requests from global distributors and customers for test kits for performance validation, reinforcing its vision to enhance global access to high-quality infectious disease diagnostics [5] - Co-Diagnostics, Inc. specializes in molecular diagnostics, focusing on the development and marketing of advanced diagnostic technologies that analyze nucleic acid molecules [7]